ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Favorable Long-Term Outcome of Late-Onset CMV Disease in D+R- Kidney Transplant Recipients Treated With Universal Prophylaxis

H. Kaminski,1 L. Couzi,1,2 I. Garrigue,3,4 J. Déchanet-Merville,2 P. Merville.1,2

1Nephrologie-Transplantation-Dialyse, CHU Bordeaux, Bordeaux, France
2Unité
Mixte de Recherche 5164, Centre National de la Recherche Scientifique, Bordeaux, France
3Laboratoire de Virologie, CHU Bordeaux, Bordeaux, France
4Unité
Mixte de Recherche 5234, Centre National de la Recherche Scientifique, Bordeaux, France.

Meeting: 2015 American Transplant Congress

Abstract number: D252

Keywords: Cytomeglovirus, Kidney transplantation, Morbidity, Prophylaxis

Session Information

Session Name: Poster Session D: Viral Infections

Session Type: Poster Session

Date: Tuesday, May 5, 2015

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Based on last international guidelines, both universal prophylaxis and preemptive strategies are viable approaches for the prevention of cytomegalovirus (CMV) disease after organ transplantation. Universal prophylaxis is used in most of the centers but leads to higher incidence of late-onset CMV disease (l-od), which has been associated with poor patient and graft survival in kidney transplant recipients (KTR). The purpose of this retrospective study was to reappraise the impact of l-od in KTR with the highest risk for CMV infection, i.e. CMV seronegative recipients transplanted with a seropositive donor (D+R-). CMV DNAemia was measured using a whole blood CMV quantitative nucleic acid amplification assay. CMV disease was defined as CMV DNAemia with viral syndrome or tissue invasive disease. Early-onset disease (e-od) was defined as occurring before 3 months and l-od after 3 months post-transplantation. Recurrence was defined as a new CMV DNAemia with clinical symptoms, after a successfully treated disease. According to the period, either universal prophylaxis for 3 to 6 months or preemptive treatment was used for CMV prevention. 168 D+R- KTR were included between 2003 and 2011, 40 with l-od, 36 with e-od and 92 without disease. 87.5% of l-od occurred after universal prophylaxis whereas 89% of e-od occurred after preemptive strategy (χ2 ; p<0.0001). Compared to patients with e-od, patients with l-od had significantly less recurrences (Odd Ratio=0.2; 95 % CI=0.08-0.5; p=0.001). Furthermore, when we compared the outcomes at three year post-transplantation of KTR with respectively l-od, e-od and no disease, the incidence of biopsy-proven acute rejection (30% vs. 18% vs. 25%, p=0.6), graft survival (90% vs. 82% vs. 93%, p=0.2) and patient survival (95% vs. 100% vs. 100%, p=0.06) were not significantly different. In D+R- KTR, universal prophylaxis is associated with late-onset disease that has better infection outcomes, and has no detrimental effect on graft and patient outcomes at three year post transplantation. These results support the use of a universal prophylaxis over a preemptive strategy in D+R- KTR.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Kaminski H, Couzi L, Garrigue I, Déchanet-Merville J, Merville P. Favorable Long-Term Outcome of Late-Onset CMV Disease in D+R- Kidney Transplant Recipients Treated With Universal Prophylaxis [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/favorable-long-term-outcome-of-late-onset-cmv-disease-in-dr-kidney-transplant-recipients-treated-with-universal-prophylaxis/. Accessed May 18, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences